Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
353
resultados
Última actualización
25/07/2026 [07:57:00]
Resultados 50 a 75 de 353
Resumen de: US20260202406A1
0000 The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of abundance or expression of immune cells, autoantibodies, and/or cytokines.
Resumen de: US20260202426A1
0000 The present disclosure relates to a method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or by using dynamic X-rays. A method of detecting a molecule associated with the diagnosis of a disease through movement of the molecules after fluorescent labeling or labeling with a crystalline plane, according to an aspect, enables large-scale imaging and Z-axis imaging, and thus can be effectively used in the field of diagnosis.
Resumen de: EP4775995A2
0001 The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: EP4775994A2
The present disclosure relates to the identification and use of biomarkers (e.g., analytes, analyte profiles, or markers (e.g., gene expression and/or protein expression profiles)) with clinical relevance to cytokine release syndrome (CRS).
Resumen de: EP4775992A2
Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
Resumen de: WO2020023899A1
The present invention is directed to methods for using particles (e.g, microparticulate, nanoparticulate; magnetic, non-magnetic) comprising surfaces comprising capture moieties as described herein, to remove an interference as described herein, or enrich biomarkers, prior to a diagnostic test.
Resumen de: CN113614540A
Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy and more specifically for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.
Resumen de: WO2021165465A1
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
Resumen de: WO2021211935A1
The invention provides methods for enriching extracellular vesicles (EVs), including exosomes, from biological fluid samples from subjects, and optionally further testing the EVs for the presence of specific biomarkers.
Resumen de: WO2025005697A1
The present invention relates to a composition for diagnosing Parkinson's disease, comprising an agent for detecting a protein consisting of a combination of GLUT3 and any one or more selected from the group consisting of USP14, α-synuclein, and AIMP2, or a gene encoding the protein. The composition for diagnosing Parkinson's disease and a diagnostic kit comprising the composition, of the present invention, can be used to perform detection or diagnosis by distinguishing Parkinson's disease patient groups through a simple blood test. Furthermore, by primarily applying same to patients showing prodromal symptoms of Parkinson's disease, such as olfactory dysfunction, sleep disorders, and constipation, the composition and the diagnostic kit can be used as a preliminary test to determine whether to perform neurological examinations and brain imaging tests at large hospitals. Also, the composition and the diagnostic kit can be used as a means for quantifying the effect of treating Parkinson's disease.
Resumen de: WO2024254151A2
Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.
Resumen de: WO2024254190A2
The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
Resumen de: WO2025008357A1
Acute decompensation (AD) of cirrhosis is defined by the acute development of ascites, gastrointestinal haemorrhage, hepatic encephalopathy or infection. The PREDICT study distinguishes three different phenotypic sub-types in patients with AD but without ACLF according to hospital readmission and development of ACLF: stable decompensated cirrhosis, unstable decompensated cirrhosis and pre-ACLF group. Predicting the phenotypes in patients with AD would thus be useful, since mortality rates vary considerably between the three phenotypes. This will allow us a better management of patients with AD. Now the inventors used proteomics analysis of proteins carried by plasma lEVs to identify novel EV protein biomarkers having higher concentrations in the plasma of patients who will develop organ failure than in those who will not (Tenascin C and 0LFM4 lEVs). Moreover, the inventors identified 2 plasma lEVs (FCGBP and Tenascin C) predicting survival in PREDICT. Tenascin C was the most robust one since also predicting survival in ACLARA. Accordingly, the present invention relates to large extracellular vesicles as biomarkers for predicting organ failures and survival time of patients suffering from an acute decompensation of cirrhosis.
Resumen de: EP3859331A1
0001 The present invention relates to methods for assigning a phenotypic signature of cells in a liquid biological sample obtained from a mammal, to an innate immune response group using multivariate classification algorithms. Furthermore, the present invention relates to a method for identifying whether a mammal suffers from an inflammation-related disease or is at risk of suffering from an inflammation-related disease using the phenotypic signature. Moreover, the present invention relates to a method for stratifying a mammal suffering from an inflammation-related disease for a treatment against said inflammation-related disease. In addition, the present invention relates to a method for monitoring the progression of an inflammation-related disease in a mammal during a treatment of said mammal. Also, the present invention relates to a method for identifying a compound and/or environmental condition that induces or represses the innate immune response of cells obtained from a mammal. Furthermore, the present invention relates to a use of said phenotypic signature for diagnostic and/or drug de-risking applications.
Resumen de: CN122356501A
0001 本发明公开了一种铈掺杂高熵金属有机框架纳米酶及其制备方法、检测β‑淀粉样蛋白1‑42的方法，属于纳米材料制备与分析化学交叉领域。其制备过程包括：将N,N‑二甲基甲酰胺、无水乙醇、超纯水、甘油和聚乙烯吡咯烷酮混合均匀；加入对苯二甲酸以及等摩尔量的可溶性三价铁盐、三价铈盐、二价钴盐、二价铜盐和二价镍盐；加入三乙胺在pH为9.0
9.5条件下搅拌反应并超声处理，然后将产物依次离心分离收集沉淀、洗涤和干燥，得到目标产品。本发明的纳米酶具有超宽的线性检测范围和良好的长期稳定性，适用于对目标分析物β‑淀粉样蛋白1‑42的快速、精准检测，为特定目标蛋白质的体外浓度监测与生化指标评估提供技术手段。
Resumen de: CN122361564A
本发明属于生物传感技术领域，具体涉及一种用于检测活性乙酰胆碱酯酶的生物传感器及其应用。包括尖端具有纳米孔径的纳米管，用于产生电流阻断信号；环束DNA四面体载体，用于负载含活性乙酰胆碱酯酶的待检测溶液，环束DNA四面体载体为TDN1或TDN4，TDN1中的四条DNA单链的序列如SEQ ID NO.1至SEQ ID NO.4所示，TDN4中四条DNA单链的序列如SEQ ID NO.1、SEQ ID NO.3、SEQ ID NO.5和SEQ ID NO.6所示。本发明利用一种适配体两端锚定的闭环DNA四面体纳米结构，与活性AChE结合前后在纳米孔中产生电流信号差异，实现在单分子水平上对活性AChE的高灵敏和高选择性检测。
Resumen de: CN122361823A
0001 本发明公开基于机器学习的表面增强拉曼光谱检测Tau蛋白方法、系统及装置，该方法包括以下步骤：S1、构建具有最小初始拉曼信号的SERS信号探针；S2、将待测样本与所述SERS信号探针混合，利用拉曼光谱仪采集得到混合体系的SERS光谱；S3、对采集到的所述SERS光谱进行预处理，所述预处理包括依次进行的基线校正、特征峰识别及最小‑最大归一化处理，得到标准化的光谱数据；S4、将所述标准化的光谱数据输入至预先训练好的机器学习回归模型中，由所述机器学习回归模型基于输入的光谱特征自动输出待测样本中Tau蛋白的浓度值。本发明能够在保持高特异性的前提下，快速、准确、低检测限地定量检测磷酸化Tau蛋白，具有高临床转化潜力。
Resumen de: CN122361824A
0001 本发明涉及化学发光免疫分析技术领域，具体涉及一种提高p‑tau 217项目发光水平的磁珠包被方法及应用，本发明优化羧基磁珠包被p‑tau 217捕获抗体工艺，通过梯度调整EDC、NHS的投入比例，获得最适活化剂浓度以增强磁珠偶联活性，增大了抗体的偶联效率，进而提高了抗原样本与临床样本的信号值，对于p‑tau 217等低丰度蛋白的高灵敏检测的开发具有广阔的应用前景。
Resumen de: WO2024255846A1
Provided herein are oligonucleotide formulations. In particular, it relates to formulations of oligonucleotide comprising oligonucleotide (such as ASO, siRNA, saRNA) and calcium, methods the preparation of the formulation, and use thereof. The oligonucleotide formulations have reduced in vivo acute toxicity (especially in central nervous system) and expanded in vivo safety window for the oligonucleotides especially the lipid conjugate, and thus having great application prospect.
Resumen de: CN122356282A
0001 本发明提供了一种识别ApoE4的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK29，包括HZK29‑B0009、HZK29‑B0010和HZK29‑B0019。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE4。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。
Resumen de: CN122356237A
0001 本发明涉及药物技术领域，尤其涉及一种抑制和/或清除β‑淀粉样蛋白聚集的多肽及其应用。本发明首先开发出了可从多靶点作用对阿尔茨海默病等β‑淀粉样蛋白聚集和沉积所引发的疾病发挥作用的功能性活性多肽ANI‑1，以对疾病起到有效的预防及其治疗的效果，本发明的多肽ANI‑1具有清除Aβ聚集、延缓β‑淀粉样蛋白毒性导致的行为衰退（抗瘫痪、促运动）、抑制β‑淀粉样蛋白沉积相关的神经性炎症并增强抗氧化防御的功能，具有更好的整体疗效和神经保护潜力，可为开发出多靶点的针对阿尔茨海默病等β‑淀粉样蛋白聚集和沉积所引发的疾病的多靶点药物提供新的思路。
Resumen de: CN120064427A
The invention discloses a method for detecting spatial distribution of brain nucleic acid hydrolysate based on mass spectrum imaging and an analysis system.The method comprises the steps of sample preparation, mass spectrum imaging and spatial quantitative analysis of nucleic acid hydrolysate, specifically, a spray needle capillary tube with the diameter being 10-30 micrometers is adopted, the angle between a spray needle and a sample glass slide is adjusted to be 55-57 degrees, the height is 35-36.5 mm, and the sample glass slide is placed in the sample capillary tube; the method comprises the following steps: uniformly spraying a spray solvent on the surface of a brain slice, scanning the whole sample to obtain mass spectrum imaging data, extracting the ion strength of target objects corresponding to different brain regions according to the monitored ion mass-to-charge ratio of the nucleic acid hydrolysate, and obtaining the spatial distribution of the nucleic acid hydrolysate in the different brain regions of the brain; the analysis system can extract the ion strength of the target object corresponding to the different brain regions according to the obtained brain mass spectrum and the monitored ion mass-to-charge ratio of the target object, the spatial distribution of the target object in the different brain regions is obtained, and spatial difference analysis among different groups is completed.
Resumen de: US20260196299A1
0000 Methods, systems, and kits are provided for assessing cardiorespiratory fitness and predicting cardiometabolic risk.
Resumen de: WO2026146787A1
The purpose of the present invention is to develop a design strategy focusing on central secondary structure motifs, such as α-helix, β-strand, and β-turn, which are important for PPI recognition, by using a common core skeleton, thereby providing a low-molecular-weight PPI modulator having a wide range of therapeutic potentials, and a versatile platform for targeting PPI.
Nº publicación: US20260194539A1 09/07/2026
Solicitante:
GWANGJU INST OF SCIENCE AND TECHNOLOGY [KR]
SEOUL NATIONAL UNIV R&DB FOUNDATION [KR]
INDUSTRY ACADEMIC COOPERATION FOUNDATION CHOSUN UNIV [KR]
GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
Resumen de: US20260194539A1
A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
BOPI
Sede Electrónica
